CDK5 genetic markers associated with galantamine response
View Patent ↗Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
1. A method for determining whether an individual has a galantamine response marker I, a galantamine response marker II, or a galantamine response marker III in said individual's cyclin-dependent kinase 5 (CDK5) gene, the method comprising:
determining whether the individual has zero copies, one copy, or two copies of any of (a) haplotype (1), (b) a linked haplotype for haplotype (1), and (c) a substitute haplotype for haplotype (1), wherein haplotype (1) has a G at polymorphic sites (PSs) 3 and 4 of the CDK5 gene (SEQ ID NO:1), and wherein polymorphic site (PS) 3 is at nucleotide position 4808 and PS4 is at nucleotide position 5284 of SEQ ID NO:1, wherein the individual has a galantamine response marker I if the individual has zero copies of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1), the individual has a galantamine response marker II if the individual has one copy of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1), and the individual has a galantamine response marker III if the individual has two copies of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1).
2. The method of claim 1 , wherein said determining comprises obtaining the individual's genotype for least one PS in the set of PSs that comprises (a) said haplotypes (1); (b) said linked haplotype for haplotypes (1); or (c) said substitute haplotype for haplotypes (1).
3. The method of claim 2 , wherein the individual's genotype for the set of PSs is obtained by any of (a) a primer extension assay; (b) an allele-specific PCR assay; (c) a nucleic acid amplification assay; (d) a hybridization assay; (e) a mismatch-detection assay; (f) an enzymatic nucleic acid cleavage assay; and (g) a sequencing assay.
4. The method of claim 1 , wherein the determining comprises consulting a data repository that provides information on the individual's copy number for haplotypes (1), a linked haplotype for haplotypes (1), or a substitute haplotype for haplotype (1).
5. The method of claim 4 , wherein the data repository is the individual's medical records or a medical data card.
6. The method of claim 1 or claim 2 , wherein the method comprises determining whether an individual has zero copies, one copy, or two copies of said haplotype (1).
7. The method of claim 1 , wherein the linkage disequilibrium between the linked haplotype and haplotypes (1) has a delta squared value selected from the group consisting of at least 0.75, at least 0.80, at least 0.85, at least 0.90, at least 0.95, and 1.0.
8. The method of claim 7 , wherein the linkage disequilibrium between the linked haplotype and haplotype (1) has a delta squared value of at least 0.95.
9. The method of claim 1 , wherein the linkage disequilibrium between the allele at a substituting PS in the substitute haplotype and the allele at a substituted PS in haplotypes (1) has a delta squared value selected from the group consisting of at least 0.75, least 0.80, at least 0.85, at least 0.90, at least 0.95, and 1.0.
10. The method of claim 9 , wherein the linkage disequilibrium between the allele at a substituting PS and the allele at a substituted PS in haplotype (1) in Table 1 has a delta squared value of at least 0.95.
11. The method of claim 1 , wherein the individual is Caucasian.
12. The method of claim 1 , wherein the individual is diagnosed as having a cognitive disorder.
13. The method of claim 1 , wherein the individual is a candidate for treatment with a galantamine compound.
14. A method for assigning an individual to a first galantamine response marker group, a second galantamine response marker group, or a third galantamine response marker group based on the galantamine response marker present in said individual's cyclin-dependent kinase 5 (CDK5) gene, the method comprising:
determining whether the individual has zero copies, one copy, or two copies of any of (a) haplotype (1), (b) a linked haplotype for haplotype (1), and (c) a substitute haplotype for haplotype (1), wherein haplotype (1) has a G at the polymorphic sites (PSs) 3 and 4 of the CDK5 gene (SEQ ID NO:1), and wherein polymorphic site (PS) 3 is at nucleotide position 4808 and PS4 is at nucleotide position 5284 of SEQ ID NO:1; and
assigning the individual to the first galantamine response marker group if the individual has zero copies of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1), assigning the individual to the second galantamine response marker group if the individual has one copy of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1), and assigning the individual to the third galantamine response marker group if the individual has two copies of any of (a) said haplotype (1), (b) said linked haplotype for haplotype (1), and (c) said substitute haplotype for haplotype (1).
15. The method of claim 14 , wherein the determining comprises obtaining the individual's genotype for at least one PS in the set of PS that comprise (a) said haplotypes (1); (b) said linked haplotype for haplotypes (1); or (c) said substitute haplotype for haplotype (1).
16. The method of claim 15 , wherein the individual's genotype for the set of PSs is obtained by any of (a) a primer extension assay; (b) an allele-specific PCR assay; (c) a nucleic acid amplification assay; (d) a hybridization assay; (e) a mismatch-detection assay; (f) an enzymatic nucleic acid cleavage assay; and (g) a sequencing assay.
17. The method of claim 14 , wherein the determining comprises consulting a data repository that provides information on the individual's copy number for any of (a) haplotype (1), (b) a linked haplotype for haplotype (1), or (c) a substitute haplotype for haplotype (1).
18. The method of claim 17 , wherein the data repository is the individual's medical records or a medical data card.
19. The method of claim 14 , wherein the method comprises:
determining whether the individual has zero copies, one copy, or two copies of said haplotype (1); and
assigning the individual to the first galantamine response marker group if the individual has zero copies of haplotype (1), assigning the individual to the second galantamine response marker group if the individual has one copy of haplotype (1), and assigning the individual to the third galantamine response marker group if the individual has two copies of haplotype (1).
20. The method of claim 14 , wherein the individual is Caucasian.
21. The method of claim 14 , wherein the individual is diagnosed as having a cognitive disorder.
22. The method of claim 14 , wherein the individual is a candidate for treatment with a galantamine compound.
23. The method of claim 14 , wherein the linkage disequilibrium between the linked haplotype and haplotype (1) has a delta squared value selected from the group consisting of at least 0.75, at least 0.80, at least 0.85, at least 0.90, at least 0.95, and 1.0.
24. The method of claim 23 , wherein the linkage disequilibrium between the linked haplotype and haplotype (1) has a delta squared value of at least 0.95.
25. The method of claim 14 , wherein the linkage disequilibrium between the allele at a substituting PS in the substitute haplotype and the allele at a substituted PS in haplotype (1) has a delta squared value selected from the group consisting of at least 0.75, at least 0.80, at least 0.85, at least 0.90, at least 0.95, and 1.0.
26. The method of claim 25 , wherein the linkage disequilibrium between the allele at a substituting PS and the allele at a substituted PS in haplotype (1) has a delta squared value of at least 0.95.